Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Colorectal Neoplasms

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 110 articles: HTML format

Single Articles

June 2021
1. OSUMI H, Vecchione L, Keilholz U, Vollbrecht C, et al
   NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature.
   Eur J Cancer. 2021;153:86-95.
   PubMed     Abstract available
   
   
   
2. BRETON C, Aparicio T, Le Malicot K, Ducreux M, et al
   Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Federation Francophone de Cancerologie Digestive (FFCD) trials.
   Eur J Cancer. 2021;153:40-50.
   PubMed     Abstract available
   
   
   
3. MORETTO R, Giordano M, Poma AM, Passardi A, et al
   Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
   Eur J Cancer. 2021;153:16-26.
   PubMed     Abstract available
   
   
   May 2021
4. EL-KHOURY R, Hafliger E, Gallois C, Louafi S, et al
   Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer.
   Eur J Cancer. 2021;152:1-3.
   PubMed    
   
   
   
5. SAESEN R, Lacombe D, Huys I
   Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer.
   Eur J Cancer. 2021;151:221-232.
   PubMed     Abstract available
   
   
   
6. SATTLER EC, Syunyaeva Z, Reithmair M, Dempke W, et al
   Colorectal cancer risk in families with Birt-Hogg-Dube syndrome increased.
   Eur J Cancer. 2021;151:168-174.
   PubMed     Abstract available
   
   
   April 2021
7. CORTI F, Lonardi S, Intini R, Salati M, et al
   The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
   Eur J Cancer. 2021;150:155-167.
   PubMed     Abstract available
   
   
   
8. ARAI H, Millstein J, Loupakis F, Stintzing S, et al
   Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
   Eur J Cancer. 2021;150:133-142.
   PubMed     Abstract available
   
   
   March 2021
9. ROSATI G, Lonardi S, Galli F, Di Bartolomeo M, et al
   Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
   Eur J Cancer. 2021;148:190-201.
   PubMed     Abstract available
   
   
   February 2021
10. HEINRICH K, Modest DP, Ricard I, Fischer von Weikersthal L, et al
    Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
    Eur J Cancer. 2021;147:128-139.
    PubMed     Abstract available
    
    
    
11. STAMMLER R, Gallois C, Taieb J, Duong JP, et al
    Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer.
    Eur J Cancer. 2021;147:60-62.
    PubMed    
    
    
    
12. MALAPELLE U, Passiglia F, Cremolini C, Reale ML, et al
    RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
    Eur J Cancer. 2021;146:74-83.
    PubMed     Abstract available
    
    
    January 2021
13. JONES RP, Pugh SA, Graham J, Primrose JN, et al
    Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Eur J Cancer. 2021;144:368-381.
    PubMed     Abstract available
    
    
    
14. DALL'ARMELLINA F, Perret A, Smolenschi C, Hollebecque A, et al
    Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus.
    Eur J Cancer. 2021;142:147-149.
    PubMed    
    
    
    December 2020
15. KASPER S, Foch C, Messinger D, Esser R, et al
    Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2020;144:291-301.
    PubMed     Abstract available
    
    
    
16. DEN UIL SH, de Wit M, Slebos RJC, Delis-van Diemen PM, et al
    Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
    Eur J Cancer. 2020;144:91-100.
    PubMed     Abstract available
    
    
    
17. NAKAYAMA G, Takano N, Taniguchi H, Ishigure K, et al
    Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
    Eur J Cancer. 2020;144:61-71.
    PubMed     Abstract available
    
    
    
18. MANCA P, Corallo S, Randon G, Lonardi S, et al
    Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2020;144:31-40.
    PubMed     Abstract available
    
    
    
19. COLLE R, Radzik A, Cohen R, Pellat A, et al
    Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Eur J Cancer. 2020;144:9-16.
    PubMed     Abstract available
    
    
    
20. LERMAN J, Hennequin C, Etienney I, Abramowitz L, et al
    Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer.
    Eur J Cancer. 2020;141:143-151.
    PubMed     Abstract available
    
    
    November 2020
21. BOLHUIS K, Kos M, van Oijen MGH, Swijnenburg RJ, et al
    Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
    Eur J Cancer. 2020;141:225-238.
    PubMed     Abstract available
    
    
    October 2020
22. TOKUNAGA R, Xiu J, Goldberg RM, Philip PA, et al
    The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Eur J Cancer. 2020;140:119-129.
    PubMed     Abstract available
    
    
    
23. MALKA D, Lievre A, Andre T, Taieb J, et al
    Immune scores in colorectal cancer: Where are we?
    Eur J Cancer. 2020;140:105-118.
    PubMed     Abstract available
    
    
    
24. BOILEVE A, De Cuyper A, Larive A, Mahjoubi L, et al
    Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
    Eur J Cancer. 2020;138:89-98.
    PubMed     Abstract available
    
    
    September 2020
25. MORETTO R, Rossini D, Zucchelli G, Lonardi S, et al
    Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
    Eur J Cancer. 2020;139:81-89.
    PubMed     Abstract available
    
    
    
26. SOBRERO AF, Puccini A, Shi Q, Grothey A, et al
    A new prognostic and predictive tool for shared decision making in stage III colon cancer.
    Eur J Cancer. 2020;138:182-188.
    PubMed     Abstract available
    
    
    August 2020
27. TSAI HL, Huang CW, Lin YW, Wang JH, et al
    Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Eur J Cancer. 2020;138:19-29.
    PubMed     Abstract available
    
    
    
28. CARDONE C, Blauensteiner B, Moreno-Viedma V, Martini G, et al
    AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2020;138:1-10.
    PubMed     Abstract available
    
    
    
29. STAHLER A, Stintzing S, von Einem JC, Westphalen CB, et al
    Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
    Eur J Cancer. 2020;137:250-259.
    PubMed     Abstract available
    
    
    
30. TEUFEL A, Gerken M, Furst A, Ebert M, et al
    Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer.
    Eur J Cancer. 2020;137:148-160.
    PubMed     Abstract available
    
    
    
31. MARTIN-ROMANO P, Ammari S, El-Dakdoukti Y, Baldini C, et al
    Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
    Eur J Cancer. 2020;137:117-126.
    PubMed     Abstract available
    
    
    
32. KURRECK A, Heinemann V, Fischer von Weikersthal L, Decker T, et al
    Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
    Eur J Cancer. 2020;137:81-92.
    PubMed     Abstract available
    
    
    
33. SMITH HG, Glen J, Turnbull N, Peach H, et al
    Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma.
    Eur J Cancer. 2020;135:113-120.
    PubMed     Abstract available
    
    
    
34. MORETTO R, Corallo S, Belfiore A, Rossini D, et al
    Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
    Eur J Cancer. 2020;135:78-88.
    PubMed     Abstract available
    
    
    
35. MANS L, Pezzullo M, D'Haene N, Van de Stadt J, et al
    Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?
    Eur J Cancer. 2020;135:75-77.
    PubMed    
    
    
    
36. SMITH HG, Bagwan I, Board RE, Capper S, et al
    Ano-uro-genital mucosal melanoma UK national guidelines.
    Eur J Cancer. 2020;135:22-30.
    PubMed     Abstract available
    
    
    July 2020
37. RAIMONDI A, Di Maio M, Morano F, Corallo S, et al
    Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
    Eur J Cancer. 2020;135:230-239.
    PubMed     Abstract available
    
    
    June 2020
38. SAKAI D, Taniguchi H, Sugimoto N, Tamura T, et al
    Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Eur J Cancer. 2020;135:11-21.
    PubMed     Abstract available
    
    
    May 2020
39. PASQUALETTI G, Schirripa M, Dochy E, Fassan M, et al
    Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial.
    Eur J Cancer. 2020;133:66-73.
    PubMed     Abstract available
    
    
    April 2020
40. BERGER MD, Ning Y, Stintzing S, Heinemann V, et al
    A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
    Eur J Cancer. 2020;131:89-97.
    PubMed     Abstract available
    
    
    March 2020
41. ZLOBEC I, Dawson HE, Blank A, Bokhorst JM, et al
    Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients.
    Eur J Cancer. 2020;130:139-145.
    PubMed     Abstract available
    
    
    
42. KLINKHAMMER-SCHALKE M, Steinger B, Koller M, Zeman F, et al
    Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer.
    Eur J Cancer. 2020;130:102-113.
    PubMed     Abstract available
    
    
    
43. COHEN R, Vernerey D, Bellera C, Meurisse A, et al
    Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
    Eur J Cancer. 2020;130:63-71.
    PubMed     Abstract available
    
    
    
44. KIM JW, Han SW, Cho JY, Chung IJ, et al
    Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial.
    Eur J Cancer. 2020;130:51-62.
    PubMed     Abstract available
    
    
    
45. GILBERT A, Drinkwater K, McParland L, Adams R, et al
    UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Eur J Cancer. 2020;128:7-16.
    PubMed     Abstract available
    
    
    
46. LORD AC, Knijn N, Brown G, Nagtegaal ID, et al
    Pathways of spread in rectal cancer: a reappraisal of the true routes to distant metastatic disease.
    Eur J Cancer. 2020;128:1-6.
    PubMed     Abstract available
    
    
    February 2020
47. LUQUE-FERNANDEZ MA, Goncalves K, Salamanca-Fernandez E, Redondo-Sanchez D, et al
    Multimorbidity and short-term overall mortality among colorectal cancer patients in Spain: A population-based cohort study.
    Eur J Cancer. 2020;129:4-14.
    PubMed     Abstract available
    
    
    January 2020
48. BHARDWAJ M, Weigl K, Tikk K, Holland-Letz T, et al
    Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer.
    Eur J Cancer. 2020;127:30-40.
    PubMed     Abstract available
    
    
    
49. FASTNER G, Sedlmayer F, Widder J, Metz M, et al
    Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.
    Eur J Cancer. 2020;127:12-20.
    PubMed     Abstract available
    
    
    
50. GINI A, Jansen EEL, Zielonke N, Meester RGS, et al
    Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review.
    Eur J Cancer. 2020 Jan 10. pii: S0959-8049(19)30870.
    PubMed     Abstract available
    
    
    
51. ROMBOUTS AJM, Hugen N, Elferink MAG, Poortmans PMP, et al
    Increased risk for second primary rectal cancer after pelvic radiation therapy.
    Eur J Cancer. 2020;124:142-151.
    PubMed     Abstract available
    
    
    November 2019
52. SUMMERS MG, Maughan TS, Kaplan R, Law PJ, et al
    Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
    Eur J Cancer. 2019;124:56-63.
    PubMed     Abstract available
    
    
    
53. DUCREUX M, Petersen LN, Ohler L, Bergamo F, et al
    Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Eur J Cancer. 2019;123:146-154.
    PubMed     Abstract available
    
    
    October 2019
54. SOLDEVILLA B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, et al
    The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Eur J Cancer. 2019;123:118-129.
    PubMed     Abstract available
    
    
    August 2019
55. MUNEMOTO Y, Nakamura M, Takahashi M, Kotaka M, et al
    SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    Eur J Cancer. 2019;119:158-167.
    PubMed     Abstract available
    
    
    
56. GALLOIS C, Artru P, Lievre A, Auclin E, et al
    Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.
    Eur J Cancer. 2019;119:35-43.
    PubMed     Abstract available
    
    
    July 2019
57. LOUPAKIS F, Intini R, Cremolini C, Orlandi A, et al
    A validated prognostic classifier for (V600E)BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.
    Eur J Cancer. 2019;118:121-130.
    PubMed     Abstract available
    
    
    
58. MILANO G
    More rationale for optimal sequencing of therapeutic monoclonal antibodies in metastatic colorectal cancer.
    Eur J Cancer. 2019;117:131-132.
    PubMed    
    
    
    June 2019
59. BROUWER NPM, Heil TC, Olde Rikkert MGM, Lemmens VEPP, et al
    The gap in postoperative outcome between older and younger patients with stage I-III colorectal cancer has been bridged; results from the Netherlands cancer registry.
    Eur J Cancer. 2019;116:1-9.
    PubMed     Abstract available
    
    
    May 2019
60. VAUGHAN-SHAW PG, Zgaga L, Theodoratou E, Blackmur JP, et al
    Whether vitamin D supplementation protects against colorectal cancer risk remains an open question.
    Eur J Cancer. 2019;115:1-3.
    PubMed    
    
    
    March 2019
61. ARGILES G, Andre T, Hollebecque A, Calvo A, et al
    Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Eur J Cancer. 2019;112:12-19.
    PubMed     Abstract available
    
    
    
62. PUCCINI A, Loupakis F, Stintzing S, Cao S, et al
    Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.
    Eur J Cancer. 2019;111:138-147.
    PubMed     Abstract available
    
    
    February 2019
63. KOSUMI K, Hamada T, Zhang S, Liu L, et al
    Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Eur J Cancer. 2019;111:82-93.
    PubMed     Abstract available
    
    
    
64. CASCINU S, Poli D, Zaniboni A, Lonardi S, et al
    The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
    Eur J Cancer. 2019;111:1-7.
    PubMed     Abstract available
    
    
    
65. ANDERSSON TM, Engholm G, Lund AQ, Lourenco S, et al
    Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
    Eur J Cancer. 2019;110:42-48.
    PubMed     Abstract available
    
    
    
66. CREMOLINI C, Marmorino F, Bergamo F, Aprile G, et al
    Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
    Eur J Cancer. 2019;109:175-182.
    PubMed     Abstract available
    
    
    January 2019
67. MODEST DP, Pant S, Sartore-Bianchi A
    Treatment sequencing in metastatic colorectal cancer.
    Eur J Cancer. 2019;109:70-83.
    PubMed     Abstract available
    
    
    December 2018
68. SCHWARTZ S, Szeto C, Tian Y, Cecchi F, et al
    Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Eur J Cancer. 2018;107:164-174.
    PubMed     Abstract available
    
    
    
69. SUENAGA M, Stintzing S, Cao S, Zhang W, et al
    Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
    Eur J Cancer. 2018;107:100-114.
    PubMed     Abstract available
    
    
    November 2018
70. HOLCH JW, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Eur J Cancer. 2018;106:115-125.
    PubMed     Abstract available
    
    
    
71. BARANISKIN A, Buchberger B, Pox C, Graeven U, et al
    Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2018;106:37-44.
    PubMed     Abstract available
    
    
    
72. IMANISHI M, Yamamoto Y, Hamano Y, Yamada T, et al
    Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.
    Eur J Cancer. 2018;106:69-77.
    PubMed     Abstract available
    
    
    October 2018
73. MOLOGNI L
    Synergistic activity of dasatinib in combination with beta-catenin blockade in colorectal cancer cells.
    Eur J Cancer. 2018 Oct 12. pii: S0959-8049(18)31366.
    PubMed    
    
    
    September 2018
74. SALEM ME, Yin J, Weinberg BA, Renfro LA, et al
    Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD dat
    Eur J Cancer. 2018;103:205-213.
    PubMed     Abstract available
    
    
    
75. LORD AC, D'Souza N, Pucher PH, Moran BJ, et al
    Author response to comment on 'significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis'.
    Eur J Cancer. 2018 Sep 25. pii: S0959-8049(18)31336.
    PubMed    
    
    
    
76. GOOTJES EC, Bakkerus L, Ten Tije AJ, Witteveen PO, et al
    The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer.
    Eur J Cancer. 2018;103:160-164.
    PubMed     Abstract available
    
    
    
77. HAMADA T, Liu L, Nowak JA, Mima K, et al
    Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour.
    Eur J Cancer. 2018;103:98-107.
    PubMed     Abstract available
    
    
    
78. HIRST Y, Stoffel S, Baio G, McGregor L, et al
    Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out.
    Eur J Cancer. 2018 Sep 6. pii: S0959-8049(18)31120.
    PubMed     Abstract available
    
    
    August 2018
79. MADI A, Fisher D, Maughan TS, Colley JP, et al
    Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Eur J Cancer. 2018;102:31-39.
    PubMed     Abstract available
    
    
    
80. TEJPAR S, Yan P, Piessevaux H, Dietrich D, et al
    Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Eur J Cancer. 2018;99:66-77.
    PubMed     Abstract available
    
    
    July 2018
81. ARANDA E, Garcia Alfonso P, Benavides M, Sanchez Ruiz A, et al
    First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    Eur J Cancer. 2018 Jul 24. pii: S0959-8049(18)30938.
    PubMed     Abstract available
    
    
    
82. HEGEWISCH-BECKER S, Nopel-Dunnebacke S, Hinke A, Graeven U, et al
    Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
    Eur J Cancer. 2018;101:105-113.
    PubMed     Abstract available
    
    
    
83. GELLI M, Huguenin JFL, de Baere T, Benhaim L, et al
    Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
    Eur J Cancer. 2018;100:94-103.
    PubMed     Abstract available
    
    
    June 2018
84. GOEY KKH, Sorbye H, Glimelius B, Adams RA, et al
    Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
    Eur J Cancer. 2018;100:35-45.
    PubMed     Abstract available
    
    
    
85. STOCKER G, Hacker UT, Fiteni F, John Mahachie J, et al
    Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
    Eur J Cancer. 2018;99:49-57.
    PubMed     Abstract available
    
    
    May 2018
86. APARICIO T, Ducreux M, Faroux R, Barbier E, et al
    Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
    Eur J Cancer. 2018;98:1-9.
    PubMed     Abstract available
    
    
    
87. APARICIO T, Bouche O, Francois E, Retornaz F, et al
    Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
    Eur J Cancer. 2018;97:16-24.
    PubMed     Abstract available
    
    
    
88. AUCLIN E, Andre T, Taieb J, Benetkiewicz M, et al
    Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.
    Eur J Cancer. 2018 May 3. pii: S0959-8049(18)30782.
    PubMed    
    
    
    
89. GOEY KKH, Mahmoud R, Sorbye H, Glimelius B, et al
    Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.
    Eur J Cancer. 2018;96:115-124.
    PubMed     Abstract available
    
    
    April 2018
90. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Eur J Cancer. 2018;96:105-110.
    PubMed     Abstract available
    
    
    
91. MATSUDA C, Ishiguro M, Teramukai S, Kajiwara Y, et al
    A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Eur J Cancer. 2018;96:54-63.
    PubMed     Abstract available
    
    
    March 2018
92. TACHON G, Frouin E, Karayan-Tapon L, Auriault ML, et al
    Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.
    Eur J Cancer. 2018 Mar 5. pii: S0959-8049(18)30121.
    PubMed    
    
    
    
93. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.
    Eur J Cancer. 2018;94:1-5.
    PubMed     Abstract available
    
    
    
94. OGURA A, Akiyoshi T, Yamamoto N, Kawachi H, et al
    Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
    Eur J Cancer. 2018;91:11-20.
    PubMed     Abstract available
    
    
    February 2018
95. YOSHINO T, Hsu Y, Nasroulah F
    Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
    Eur J Cancer. 2018 Feb 9. pii: S0959-8049(18)30084.
    PubMed    
    
    
    
96. ZOU D, Lou J, Ke J, Mei S, et al
    Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression.
    Eur J Cancer. 2018;93:1-9.
    PubMed     Abstract available
    
    
    January 2018
97. VAN ROOIJEN KL, Shi Q, Goey KKH, Meyers J, et al
    Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
    Eur J Cancer. 2018;91:99-106.
    PubMed     Abstract available
    
    
    
98. IBRAHIM S, Raoul W, Lecomte T, Paintaud G, et al
    Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31461.
    PubMed    
    
    
    
99. VON MOOS R, Koeberle D, Schacher S, Hayoz S, et al
    Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
    Eur J Cancer. 2018;89:82-89.
    PubMed     Abstract available
    
    
    
100. SWETS M, Kuppen PJK, Blok EJ, Gelderblom H, et al
     Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?
     Eur J Cancer. 2018;89:1-8.
     PubMed     Abstract available
     
     
     December 2017
101. VAN CUTSEM E, Mayer RJ, Laurent S, Winkler R, et al
     The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
     Eur J Cancer. 2017;90:63-72.
     PubMed     Abstract available
     
     
     November 2017
102. MODEST DP, Denecke T, Pratschke J, Ricard I, et al
     Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
     Eur J Cancer. 2017;88:77-86.
     PubMed     Abstract available
     
     
     
103. COHEN R, Buhard O, Cervera P, Hain E, et al
     Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
     Eur J Cancer. 2017;86:266-274.
     PubMed     Abstract available
     
     
     October 2017
104. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
     Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
     Eur J Cancer. 2017;86:197-206.
     PubMed     Abstract available
     
     
     
105. KEIKES L, Koopman M, Tanis PJ, Lemmens VEPP, et al
     Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.
     Eur J Cancer. 2017;86:166-177.
     PubMed     Abstract available
     
     
     
106. PREVOSTEL C, Blache P
     The dose-dependent effect of SOX9 and its incidence in colorectal cancer.
     Eur J Cancer. 2017;86:150-157.
     PubMed     Abstract available
     
     
     
107. MALKA D, Rotolo F, Boige V
     First-line treatment in metastatic colorectal cancer: Important or crucial?
     Eur J Cancer. 2017;84:363-366.
     PubMed    
     
     
     September 2017
108. TURATI F, Bravi F, Di Maso M, Bosetti C, et al
     Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and colorectal cancer risk.
     Eur J Cancer. 2017;85:86-94.
     PubMed     Abstract available
     
     
     August 2017
109. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
     Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
     Eur J Cancer. 2017;81:130-134.
     PubMed    
     
     
     January 2017
110. CHAN AK, Siriwardena AK
     Management of synchronous liver metastases and the recommendations of the second St. Gallen European Organisation for Research and Treatment of Cancer consensus conference on the management of rectal cancer.
     Eur J Cancer. 2017;71:51-52.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: